Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro

Cytokines produced by tumor cells may have various effects on antitumor immune responses and tumor growth. In the present study, the cytokine production of 31 lung cancer cell lines was evaluated, while any correlation with the histological type, the induction of tumor‐specific cytotoxic T lymphocytes (CTL) in vitro, and angiogenesis and the infiltration of inflammatory cells in tumor tissues were also examined. Production of interleukin (IL)‐1α, IL‐1β, IL‐4, IL‐6, IL‐8, IL‐10, tumor necrosis factor (TNF)‐α, granulocyte macrophage colony stimulating factor (GM‐CSF), granulocyte colony stimulating factor, transforming growth factor (TGF)‐β and vascular endothelial growth factor (VEGF) in the culture supernatant was measured using enzyme‐linked immunosorbent assay. Each cytokine was produced in a substantial number of the tumor cell lines. In particular, IL‐6, IL‐8, TGF‐β and VEGF were produced in 18 (55%), 29 (94%), 31 (100%) and 28 (90%) of 31 cell lines, respectively. However, neither IL‐4 nor TNF‐α was produced at all by any tumor cell line. TGF‐β production was significantly higher in adenocarcinoma than in squamous cell carcinoma (P = 0.03). Immunohistochemical staining revealed the magnitude of macrophage infiltration, and angiogenesis in surgically resected tumor tissue specimens correlated well with GM‐CSF and IL‐8 production from the corresponding cell lines. Among six lung cancer cell lines, CTL were induced in the three lung cancer cell lines that produced a lower amount of TGF‐β (<100 pg/mL). These findings suggested that TGF‐β produced by tumor cells could inhibit the induction of CTL in vitro. The present results suggest that the production of various cytokines from tumor cells might exert various paracrine effects both in vivo and in vitro. (Cancer Sci 2007; 98: 1048–1054)

[1]  A. Levinson,et al.  Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1 , 1990, The Journal of experimental medicine.

[2]  R. Whyte,et al.  Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma , 1994, The Journal of experimental medicine.

[3]  J. Siegfried,et al.  Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. , 1988, Cancer research.

[4]  F. Thunnissen,et al.  Histological typing of lung and pleural tumours: third edition , 2001, Journal of clinical pathology.

[5]  C. J. Burger,et al.  Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. , 1994, Journal of immunology.

[6]  Margarita Martinez-Moczygemba,et al.  Biology of common β receptor–signaling cytokines: IL-3, IL-5, and GM-CSF , 2003 .

[7]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Keller,et al.  Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.

[9]  W. Lindenmaier,et al.  Provision of 4-1BB Ligand Enhances Effector and Memory CTL Responses Generated by Immunization with Dendritic Cells Expressing a Human Tumor-Associated Antigen1 , 2003, The Journal of Immunology.

[10]  K. Sugio,et al.  Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. , 2002, Chest.

[11]  D. Metcalf The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. , 1986, Blood.

[12]  M. Awwad,et al.  The immune response to tumors. , 1989, Transplantation proceedings.

[13]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[14]  H. Broxmeyer,et al.  Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. , 2005, Blood.

[15]  M. Martinez-Moczygemba,et al.  Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. , 2003, The Journal of allergy and clinical immunology.

[16]  K. Yasumoto,et al.  Successful Induction of Tumor‐specific Cytotoxic T Lymphocytes from Patients with Non‐small Cell Lung Cancer Using CD80‐transfected Autologous Tumor Cells , 2001, Japanese journal of cancer research : Gann.

[17]  R. Prehn Tumor immunogenicity: how far can it be pushed? , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Burdick,et al.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.

[19]  N. Cascinelli,et al.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.

[20]  P. Kondaiah,et al.  Autocrine induction of tumor protease production and invasion by a metallothionein‐regulated TGF‐beta 1 (Ser223, 225). , 1992, The EMBO journal.

[21]  H. Broxmeyer,et al.  Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. , 2002, Blood.

[22]  A. Galloway,et al.  VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis , 2006, Proceedings of the National Academy of Sciences.

[23]  C. Angeletti,et al.  Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL -2-mediated neovascularization , 2000, British Journal of Cancer.

[24]  R. Kerbel,et al.  Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[26]  Y. Gong,et al.  Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. , 2001, Journal of immunology.

[27]  Y. Gong,et al.  Tumor-Derived TGF-β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine1 , 2003, The Journal of Immunology.

[28]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[29]  J. Mitchell,et al.  Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. , 2002, Cytokine.

[30]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Trinchieri,et al.  Regulation of NK cell functions by TGF-beta 1. , 1995, Journal of immunology.

[32]  H. Taguchi,et al.  Effect of serum deprivation on constitutive production of granulocyte‐colony stimulating factor and granulocyte macrophage‐colony stimulating factor in lung cancer cells , 2004, International journal of cancer.

[33]  A. Roberts,et al.  Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.

[34]  T. Tsushima,et al.  Transforming growth factor‐β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma , 2001 .

[35]  W. S. Hu,et al.  Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors. , 1996, Blood.

[36]  F. Powrie,et al.  Regulatory T cells and inflammatory bowel disease. , 1999, Immunology today.

[37]  K. Ohta,et al.  Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. , 1993, Cancer research.

[38]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[39]  R. Moy,et al.  Local expression of antiinflammatory cytokines in cancer. , 1993, The Journal of clinical investigation.

[40]  T. Tsushima,et al.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. , 2001, Cancer.

[41]  K. Yasumoto,et al.  Autologous Tumor‐specific Cytotoxic T Lymphocytes in a Patient with Lung Adenocarcinoma: Implications of the Shared Antigens Expressed in HLA‐A24 Lung Cancer Cells , 1998, Japanese journal of cancer research : Gann.

[42]  S. Dubinett,et al.  Human Non-Small Cell Lung Cancer Cells Express a Type 2 Cytokine Pattern 1 , 2006 .

[43]  M. Washington,et al.  Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. , 1996, Lung cancer.